Persistent Methicillin-Susceptible Bacteremia Rapidly Cleared with Cefazolin and Ertapenem Combination Therapy in a Patient with COVID-19 | Zendy

Dan Ilges | Zendy; Gayathri Krishnan | Zendy; Elvin Geng | Zendy

Open Access

Persistent Methicillin-Susceptible Bacteremia Rapidly Cleared with Cefazolin and Ertapenem Combination Therapy in a Patient with COVID-19

Author(s) -

Dan Ilges,

Gayathri Krishnan,

Elvin Geng

Publication year - 2022

Publication title -

case reports in infectious diseases

Language(s) - English

Resource type - Journals

eISSN - 2090-6625

pISSN - 2090-6633

DOI - 10.1155/2022/6828538

Subject(s) - ertapenem , medicine , bacteremia , cefazolin , pneumonia , clearance , covid-19 , blood culture , intensive care medicine , antibiotics , meropenem , microbiology and biotechnology , infectious disease (medical specialty) , antibiotic resistance , disease , urology , biology

Methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSIs) are associated with significant morbidity and mortality. MSSA BSIs can rapidly disseminate, resulting in deep-seated infections, prolonged durations of bacteremia, and further metastases. Recently, cefazolin and ertapenem combination therapy has emerged as a potential therapeutic strategy to sterilize the blood in patients with persistent MSSA bacteremia. Here, we present a patient with COVID-19 pneumonia and concomitant MSSA BSI achieving blood culture sterilization within 24 hours of cefazolin and ertapenem combination therapy initiation following 11 days of positive blood cultures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research